Paloma Partners’s PMV Pharmaceuticals PMVP Stock Holding History

Paloma Partners’s Portfolio PMVP Stock Details PMVP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-35,069	Closed	-$56.8K	–	1573
2024 Q2	$56.8K	Buy	+35,069	New	+$63.2K	﹤0.01%	1141

Other funds holding PMVP

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Paloma Partners's PMVP Position: Q3 2024 in Review

Paloma Partners sold out of PMV Pharmaceuticals (PMVP) in Q3 2024, closing a stake of 35,069 shares — an estimated $56.8K sold.

Paloma Partners first reported a position in PMVP in Q2 2024 and held it in 1 quarter. The position peaked at $56.8K in Q2 2024. 74 funds tracked by Wall St. Rank hold PMVP as of Q3 2024.

Paloma Partners reported no remaining PMV Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Paloma Partners sold 35,069 PMV Pharmaceuticals shares in Q3 2024, an estimated $56.8K.
Paloma Partners first reported a position in PMV Pharmaceuticals in Q2 2024 and held it in 1 quarter.
Paloma Partners's PMV Pharmaceuticals position peaked at $56.8K in Q2 2024.
74 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q3 2024.

Based on Paloma Partners's 13F filing for Q3 2024, filed 14 Nov 2024.